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Abstract
Background: The management of hypertension is a key challenge in modern health systems. This
study aimed to investigate hypertension treatment strategies among physicians specialized in
complementary and alternative medicine (CAM) in Germany by analysing prescribing patterns and
comparing these to the current treatment guidelines issued by the German Hypertension Society.
Methods: In this prospective, multicentre observational study, which included 25 primary care
physicians specialized in CAM treatment, prescriptions and diagnoses were analysed for each
consecutive hypertensive patient using routine electronic data. Data analysis was performed using
univariate statistical tests (Chi square test, Cochran-Armitage trend test). Multiple logistic
regression was used to determine factors associated with antihypertensive medication.
Results: In the year 2005, 1320 patients with 3278 prescriptions were included (mean age = 64.2
years (SD = 14.5), 63.5% women). Most patients were treated with conventional antihypertensive
monotherapies (n = 838, 63.5%). Beta-blockers were the most commonly prescribed monotherapy
(30.7%), followed by ACE inhibitors (24.0%). Combination treatment usually consisted of two
antihypertensive drugs administered either as separate agents or as a coformulation. The most
common combination was a diuretic plus an ACE inhibitor (31.2% of dual therapies). Patient
gender, age, and comorbidities significantly influenced which treatment was prescribed. 187
patients (14.2%) received one or more CAM remedies, most of which were administered in
addition to classic monotherapies (n = 104). Men (OR = 0.66; 95% CI: 0.54-0.80) and patients with
diabetes (OR = 0.55; 95% CI: 0.42-0.0.73), hypercholesterolaemia (OR = 0.59; 95% CI: 0.47-0.75),
obesity (OR = 0.74; 95% CI: 0.57-0.97), stroke (OR = 0.54; 95% CI: 0.40-0.74), or prior myocardial
infarction (OR = 0.37; 95% CI: 0.17-0.81) were less likely to receive CAM treatment.
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Conclusions: The large majority of antihypertensive treatments prescribed by CAM physicians in
the present study complied with the current German Hypertension Society treatment guidelines.
Deviations from the guidelines were observed in one of every seven patients receiving some form
of CAM treatment.
Background
The management of hypertension is a key challenge in
modern health systems. One of the most frequent chronic
conditions and the most common treatable risk factor for
cardiovascular disease, hypertension has been estimated
to account for 6% of deaths worldwide [1] and for 26% of
total mortality in Germany [2]. Hypertension was
observed in 27% of women and 30% of men in Germany
in a study by Thamm [3], and more recent studies have
reported a prevalence of more than 50% in the general
population [4].
Hypertension is the most common diagnosis made by
general practitioners (GPs) in Germany [5], and antihy-
pertensive agents are the second most frequently pre-
scribed class of drugs, accounting for 15.4% of total drug
expenditure [6]. Nevertheless, Germany is lagging behind
internationally in areas such as hypertension awareness,
treatment, and control [7]. Indeed, surveys have indicated
that 41% of patients with known hypertension in this
country are prescribed an inadequate dose of antihyper-
tensive drugs or take these at dosing intervals that deviate
from standard treatment recommendations [8]. Some
experts have also criticized the use of newer and more
expensive drugs, which in many cases may not be any
more effective than older and less expensive treatments,
such as diuretics [9].
The development, dissemination, and implementation of
hypertension treatment guidelines are a key strategy for
improving the care of hypertensive patients. Although sev-
eral such guidelines have been published in Germany
over the past decade, the most widely disseminated of
these [10] were developed by the German Hypertension
Society [11]. Moreover, recommendations have also been
published for hypertensive patients themselves to ensure
that they are kept abreast of the latest advances in treat-
ment [12,13].
Some studies have indicated that complementary and
alternative remedies from the areas of phytotherapy,
homoeopathy, or anthroposophy have potential in the
treatment of hypertension [14]. Whereas phytotherapy
involves the use of undiluted plant extracts, homoeopathy
relies on minerals, botanical substances, and other
sources in diluted form. Anthroposophic remedies
include preparations of botanical, mineral, or zoological
origin, as well as chemical substances that are either undi-
luted or based on the homoeopathic principle of high
dilution [15]. Three remedies in particular have shown
some effects in the treatment of mild to moderate hyper-
tension: crataegus [16,17], ginger [18], and Cardiodoron®
- a mixture of extracts from Hyoscyamus niger (Henbane)
and the blossoms of Primula veris (Cowslip) and Onopor-
dum acanthium (Scotch thistle) [19]. According to a sys-
tematic review by Ernst et al. [20], however, the effect sizes
of complementary and alternative remedies in the treat-
ment of hypertension are modest. To date, such remedies
have not been included in evidence-based guidelines or
patient recommendations for hypertension.
Nevertheless, the acceptance of complementary and alter-
native medicine (CAM) has grown over the past 20 years
among physicians and patients alike. Patients with
chronic diseases, such as hypertension, are increasingly
seeking CAM treatment [21-23]. As a result, a growing
number of physicians are being asked by their patients for
advice on CAM or for referrals to its practitioners [24].
An important barrier to guideline adherence is the diffi-
culty faced by physicians in reconciling patient prefer-
ences with guideline recommendations [25]. According to
studies in a variety of primary care settings, patient expec-
tations and preferences can influence the health care pro-
vided to them [26-28]. This issue may be particularly
salient in the setting of CAM, as patients seeking treatment
from physicians specialized in this field are likely to
expect to receive some form of alternative therapy. The
present study thus aims (a) to investigate adherence
among primarycare physicians specialized in CAM to the
hypertension treatment guidelines issued by the German
Hypertension Society in 2005 and (b) to examine the use
of complementary remedies among patients treated by
these physicians by analysing prescribing patterns.
Methods
In total, 25 primary care physicians in Germany partici-
pated in this prospective, multicentre observational study.
All of them were members of the EvaMed Network, which
aims to evaluate CAM remedies in usual care with regard
to prescribing patterns, efficacy, and safety [29-31]. Physi-
cians were recruited through the German National Associ-
ation of Anthroposophic Physicians (Gesellschaft
Antroposophischer Ärzte in Deutschland; GAÄD). A total of
362 physicians were contacted and informed about the
EvaMed Network by standard mail and, in the event ofBMC Family Practice 2009, 10:78 http://www.biomedcentral.com/1471-2296/10/78
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non-response, four weeks later by telephone. For a physi-
cian to be eligible to participate in the study, his or her
medical practice had to meet a number of technical
requirements, including the presence of a special compu-
terized patient documentation system (DocExpert, Doc-
Concept, TurboMed, Duria, AdamedPlus, Medistar), a
local area network (LAN) connection, and Microsoft Win-
dows and Internet Explorer (i.e. as client software). A total
of 38 physicians (10.5%) fulfilled the technical require-
ments, gave informed consent, and agreed to participate
in the EvaMed network. Of these physicians, 13 special-
ized in paediatrics and dermatology were excluded from
the study. Each of the remaining 25 physicians had prac-
tised for at least five years in primary care in addition to
completing training in anthroposophic medicine.
The present study is based on secondary data provided by
physicians. As such, the recommendations for good prac-
tice in secondary data analysis (e.g. anonymization of
data on prescriptions and diagnoses) developed by the
German Working Group on the Collection and Use of Sec-
ondary Data [32] were applied in full. In addition, the
study was approved by the responsible data security offi-
cial.
Data were included in the study if patients were at least 16
years old, had been diagnosed with hypertension, and
had received pharmacological treatment for hypertension
at least once during the study period (January-December
2005).
During the study, physicians continued to follow their
routine documentation procedures, recording diagnoses
and all prescriptions for each consecutive patient using
their existing, computerized patient documentation sys-
tem. These data were exported to the QuaDoSta post-
greSQL database hosted in each practice [33]. Physicians
used a browser-based interface to match individual diag-
noses with the corresponding drugs or remedies that had
been prescribed. Diagnoses were coded according to the
10th revision of the International Classification of Dis-
eases (ICD-10). Prescribed drugs were documented using
the German National Drug Code.
Study investigators identified all drugs and remedies pre-
scribed for hypertension (i.e. ICD-10: I10 - I15). Each sub-
stance was classified using the Anatomical Therapeutic
Chemical Index, and hypertensive drugs were clustered
into classic antihypertensives (i.e. calcium channel block-
ers (CCBs), diuretics, beta-blockers, angiotensin convert-
ing enzyme (ACE) inhibitors, angiotensin II receptor
antagonists, alpha-1 blockers, and antiadrenergic agents),
and combination treatments (e.g. diuretics and beta-
blockers, either as fixed-dose coformulations or as sepa-
rate agents).
All statistical analyses were performed using SPSS 16.0 for
Windows. Mean and standard deviations (SD) were calcu-
lated for continuous, normally distributed data. In cases
where data were not normally distributed, medians and
interquartile ranges (IQR) were reported. Subgroup anal-
yses of prescribing rates were performed for patient age
(under 40 years, 40-59 years, 60-79 years, 80 years and
older), gender, and co-morbidities (e.g. diabetes mellitus,
renal insufficiency, hypercholesterolaemia, coronary
heart disease (CHD), post myocardial infarction, heart
failure, stroke, obesity, asthma/chronic obstructive pul-
monary disease (COPD)). The two-tailed Chi square test
was used to analyse differences in prescription rates, and
the Cochran-Armitage test was used as a measure of trend.
A P value of less than 0.05 was regarded as indicating a sta-
tistically significant difference. Adjusted odds ratios (OR)
and 95% confidence intervals (CI) were calculated using
multiple logistic regression to determine factors associ-
ated with different hypertensive medications (CCBs, diu-
retics, beta-blockers, ACE inhibitors, angiotensin II
antagonists, or CAM remedies).
Results
Physicians
Of the 25 participating physicians, 21 were GPs (84%)
and 4 were internists (16%). The physicians did not differ
significantly from the overall population of physicians
certified in anthroposophy in Germany (n = 362) in terms
of age (mean = 49.4; SD = 6.3 years vs. mean = 47.5; SD =
6.1 years; P = 0.709) or gender (60.0% vs. 62.2% men; P
= 0.917), and were only slightly younger and consisted of
a similar percentage of women compared to all office-
based physicians in Germany (mean 52.0 years; 61.2%
men) [34].
Patients and prescriptions
During the study period, 8978 primary care patients
(60.5% women) were treated by the participating physi-
cians. Of the 3672 patients who were older than 16 years
(40.9%), a total of 1320 (63.5% women) met the inclu-
sion criteria (14.7%). The mean age of the included
patients was 64.2 years (SD = 14.5). A total of 1613
comorbidities were recorded (median: 1; IQR [0, 2]). The
highest comorbidity rates were seen in patients aged 60 to
79 years (1.20 in women and 1.61 in men) and patients
aged 80 years and older (1.70 in women and 1.82 in
men). In total, 32.4% of all patients had one, 19.8% had
two, and 12.8% had three or more comorbidities. Thirty-
five percent of patients (n = 462) had no reported comor-
bidities. Table 1 provides a detailed overview of comor-
bidities in participating patients.
During the study period, 1320 patients received a total of
3278 prescriptions (median prescriptions per patient and
year: 1.5; IQR [1.0, 3.0]). Most patients (n = 838; 63.5%)BMC Family Practice 2009, 10:78 http://www.biomedcentral.com/1471-2296/10/78
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received classic antihypertensive monotherapy, which
accounted for 1705 prescriptions (52.0% of all prescrip-
tions). A total of 482 patients (36.5%) received combina-
tion treatment with two antihypertensive drugs, which
accounted for 845 prescriptions (25.8% of all prescrip-
tions). Triple combinations were prescribed for 69
patients (5.2%), accounting for 104 prescriptions (3.2%
of all prescriptions).
Pharmacological therapy
A total of 187 patients (14.2%) were prescribed CAM rem-
edies, accounting for 624 prescriptions (19.1% of all pre-
scriptions). Of these prescriptions, 155 (4.7% of all
prescriptions) were for CAM remedies administered as an
adjunct to conventional therapy. Most frequently, this
involved CAM prescribed in addition to classic mono-
therapy (n = 104), especially among women (n = 79). In
total, 97 patients (7.3%) received antihypertensive CAM
treatment exclusively (i.e. without any form of conven-
tional therapy).
The most commonly prescribed agents were the beta-
blocker metoprolol (9.5%), the ACE inhibitor enalapril
(5.8%), the beta-blocker bisoprolol (4.4%), the CCB
amlodipine (3.9%), the ACE inhibitor ramipril (3.3%),
and the diuretic thiazide (3.0%). The most commonly
prescribed CAM remedies were Cardiodoron® (4.0%) and
various aurum preparations (3.8%; e.g. Aurum/Bella-
donna comp®, Aurum metallicum praeparatum®, Aurum
naturale D10/Punus spinosa, Summitates D5®).
For monotherapy, the most frequently prescribed agents
were beta-blockers (30.7%), followed by ACE inhibitors
(24.0%), CCBs (16.7%), and diuretics (15.7%). No differ-
ences could be seen in the prescription rates between the
genders for specific monotherapies, such as beta-blockers
(29.0% in men and 31.7% in women; P = 0.525) and
angiotensin II receptor antagonists (14.6% in men and
10.1% in women; P = 0.332). The overall proportion of
monotherapies also did not differ between men and
women (P = 0.079; see table 2 for details). However, there
were differences in the prescription rates for monothera-
peutic agents between the various age groups. Beta-block-
ers, for example, were prescribed most frequently in
patients aged less than 60 years, with 47.6% of patients
aged between 20 and 39 years and 39.5% of patients aged
between 40 and 59 years receiving these agents. In con-
trast, beta-blocker monotherapy was prescribed to only
28.1% of patients aged 60 to 79 years and 21.9% of
patients aged 80 years and older (P for trend < 0.001).
Among patients aged 80 years and older, diuretics
(24.3%), ACE inhibitors (24.3%), CCBs (23.7%), and
beta-blockers (21.9%) were prescribed with almost equal
frequency. Compared to the average, however, these
patients received a significantly higher proportion of
CCBs and diuretics. Only every eighth patient (12.9%)
Table 1: Sample of hypertensive patients subdivided according to comorbidities, age group, and gender
Age 
group
[years]
Total Without 
comorbidities
Comorbidities 1
Diabetes
mellitus
Renal
insufficiency
Hypercholest
erolaemia
Coronary
heart
disease
Post
myocardial
infarcttion
Heart 
failure
Stroke Obesity Asthma/
COPD
N [n (%)] [n (%)] [n (%)] [n (%)] [n (%)] [n (%)] [n (%)] [n (%)] [n (%)] [n (%)]
Under 40 23 14 (60.9) 1 (4.3) 2 (8.7) 2 (8.7) 1 (4.3) 0 (0.0) 0 (0.0) 1 (4.3) 4 (17.4) 1 (4.3)
Female 27 17 (63.0) 1 (3.7) 2 (7.4) 2 (7.4) 2 (7.4) 0 (0.0) 0 (0.0) 0 (0.0) 6 (22.2) 4 (14.8)
Male
40-59
Female 248 124 (50.0) 23 (9.3) 8 (3.2) 62 (25.0) 12 (4.8) 0 (0.0) 2 (0.8) 9 (3.6) 62 (25.0) 10 (14.9)
Male 164 63 (38.4) 19 (11.6) 9 (5.5) 69 (42.1) 18 (11.0) 5 (3.0) 1 (0.6) 5 (3.0) 50 (30.5) 9 (19.6)
60-79
Female 406 128 (31.5) 82 (20.2) 17 (4.2) 167 (41.1) 84 (20.7) 4 (1.0) 15 (3.7) 47 (11.6) 71 (17.5) 37 (55.2)
Male 247 71 (28.7) 64 (25.9) 18 (7.3) 96 (38.9) 68 (27.5) 17 (6.9) 10 (4.0) 24 (9.7) 30 (12,1) 24 (52.2)
80 or 
older
Female 161 39 (24.2) 46 (28.6) 18 (11.2) 35 (21.7) 56 (34.8) 6 (3.7) 4 (2.5) 51 (31.7) 19 (11.8) 19 (28,4)
Male 44 6 (13.6) 10 (22.7) 7 (15.9) 13 (29.5) 17 (38.6) 3 (6.8) 2 (4.5) 17 (38.6) 5 (11.4) 9 (19,6)
Total 1320 462 (35.0) 246 
(16.6)
81 (6.1) 446 (33.8) 258 
(19.5)
35 (2.7) 34 (2.6) 154 
(11.7)
247 
(18.7)
113 (8.6)
1 Double entries possibleBMC Family Practice 2009, 10:78 http://www.biomedcentral.com/1471-2296/10/78
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received other forms of antihypertensive monotherapy
(i.e. angiotensin II receptor antagonists (11.7%), alpha-1
blockers (0.2%), and antiadrenergic agents (1.0%)).
With regard to combination drug treatments (n = 845 pre-
scriptions), the most commonly prescribed option was a
diuretic plus an ACE inhibitor (31.2% of all dual thera-
pies), followed by a diuretic plus an angiotensin II recep-
tor antagonist (25.8% of all dual therapies). The latter
option was prescribed significantly more often for women
(29.1% in women vs. 19.4% in men; P = 0.018). Other
dual and triple therapies ranged far behind. The most
commonly prescribed fixed-dose coformulations were a
diuretic plus an ACE inhibitor and a diuretic plus an angi-
otensin II receptor antagonist (table 3).
Prescription rates for patients with specific comorbidities
were also compared to overall prescription rates. Patients
with heart failure were more likely to be prescribed ACE
inhibitors (32.8% versus 24.5% for all patients) and diu-
retics (23.4% versus 15.7%), and less likely to be pre-
scribed beta-blockers (12.5% versus 29.4%) (table 4).
Patients with renal insufficiency were also less likely to be
prescribed beta-blockers (15.7%), as were patients who
had experienced a myocardial infarction (18.3%); these
patients were more likely, however, to be prescribed a diu-
retic (21.3% in patients with renal insufficiency and
23.3% in patients after myocardial infarction).
With regard to combination treatments, patients with
heart failure were more likely to be prescribed an ACE
inhibitor plus a diuretic (60% versus 31.3% for all
patients), as were patients with renal insufficiency
(40.7%). Patients with diabetes were more likely to
receive a diuretic plus an angiotensin II receptor antago-
nist than an ACE inhibitor plus a diuretic (28.4% versus
25.1%; see table 5).
Factors associated with specific hypertensive agents
Table 6 shows the adjusted OR for factors associated with
specific antihypertensive agents independent of treatment
regimen. Patient gender, age, and comorbidities had an
impact on which treatment was prescribed. Men were
more likely to receive an ACE inhibitor (OR = 1.44; 95%
CI 1.20-1.74) or an angiotensin II receptor antagonist
(OR = 1.62; 95% CI 1.26-2.09), but were less likely to
receive a CAM remedy (OR = 0.66; 95% CI 0.54-0.80).
Patients older than 60 were more likely to be prescribed a
CCB (OR = 1.70; 95% CI 1.34-2.14), whereas patients
under 60 were more likely to be prescribed a beta-blocker
Table 2: Prescription of monotherapies according to age group and gender
Antihypertensives Total Gender Age group [years]
Male Female Under 40 40-59 60-79 80 or older
[N (%)] [n (%)] [n (%)] [n (%)] [n (%)] [n (%)] [n (%)]
CCBs1 285 (16.7) 101 (16.2) 184 (17.0) 12 (19.0) 47 (9.1) 148 (18.5) 78 (23.7)
- with CAM2 9 27 -162
Diuretics 267 (15.7) 88 (14.1) 179 (16.6) 9 (14.3) 71 (13.7) 107 (13.4) 80 (24.3)
- with CAM 28 82 011 6 92
Beta-blockers 523 (30.7) 181 (29.0) 342 (31.7) 23 (36.5) 204 (39.5) 224 (28.1) 72 (21.9)
- with CAM 27 72 0181 5 3
ACE inhibitors 409 (24.0) 158 (25.3) 251 (23.2) 17 (27.0) 106 (20.5) 206 (25.9) 80 (24.3)
- with CAM 23 32 0161 0 6
Angiotensin II antagonists 200 (11.7) 91 (14.6) 109 (10.1) 1 (1.6) 79 (15.3) 104 (13.1) 16 (4.9)
- with CAM 17 51 2-782
Alpha-1 blockers 4 (0.2) 2 (0.3) 2 (0.2) - 3 (0.6) 1 (0.1) -
- with CAM 0 -- ----
Antiadrenergic agents 17 (1.0) 4 (0.6) 13 (1.2) 1 (1.6) 7 (1.4) 6 (0.8) 3 (0.9)
- with CAM - -- ----
Total 1705 (100) 625 (100) 1080 (100) 63 (100) 517 (100) 796 (100) 329 (100)
1 Calcium channel blockers, 1 complementary and alternative remediesBMC Family Practice 2009, 10:78 http://www.biomedcentral.com/1471-2296/10/78
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Table 3: Prescription of combination therapy according to age group and gender
Antihypertensives Total Gender Age group [years]
Male Female Under 40 40-59 60-79 80 or older
[N (%)] [n (%)] [n (%)] [n (%)] [n (%)] [n (%)] [n (%)]
2-drug combinations 845 (100) 288 (100) 557 (100) 29 (100) 192 (100) 470 (100) 154 (100)
Diuretic plus
Beta-blocker
- Fixed-dose coformulation 67 (7.9) 12 (4.1) 55 (9.9) 5 (17.2) 19 (9.9) 33 (7.0) 10 (6.5)
- Monopreparation 53 (6.3) 15 (5.2) 38 (6.8) 1 (3.4) 19 (9.9) 24 (5.1) 9 (5.8)
CCB1
- Fixed-dose coformulation 1 (0.1) 1 (0.3) - - - 1 (0.2) -
- Monopreparation 30 (3.6) 11 (3.8) 19 (3.4) - 3 (1.6) 15 (3.2) 12 (7.8)
ACE inhibitor
- Fixed-dose coformulation 208 (24.6) 72 (25.0) 136 (24.4) 1 (3.4) 41 (21.4) 128 (27.2) 38 (24.7)
- Monopreparation 56 (6.6) 23 (8.0) 33 (5.9) - 9 (4.7) 32 (6.8) 15 (9.7)
Angiotensin II antagonist
- Fixed-dose coformulation 207 (24.5) 55 (19.1) 152 (27.3) 2 (6.9) 45 (23.4) 126 (26.8) 34 (22.1)
- Monopreparation 11 (1.3) 1 (0.3) 10 (1.8) - 2 (1.0) 5 (1.1) 4 (2.6)
CCBs plus
Beta-blocker
- Fixed-dose coformulation - ----- -
- Monopreparation 38 (4.5) 13 (4.5) 25 (4.5) 10 (34.5) 4 (2.1) 20 (4.3) 4 (2.6)
ACE inhibitor
- Fixed-dose coformulation 1 (0.1) 1 (0.3) - - - 1 (0.2) -
- Monopreparation 30 (3.6) 11 (3.8) 19 (3.4) 1 (3.4) 9 (4.7) 16 (3.4) 4 (2.6)
Angiotensin II antagonist
- Fixed-dose coformulation - ----- -
- Monopreparation 20 (2.4) 9 (3.1) 11 (2.0) - 4 (2.1) 14 (3.0) 2 (1.3)
Beta-blockers plus
Other antihypertensive
- Fixed-dose coformulation 5 (0.6) -5  ( 0 . 9 ) - -4  ( 0 . 9 ) 1  ( 6 . 0 )
- Monopreparation 81 (9.6) 52 (18.1) 29 (5.2) 7 (24.1) 33 (17.2) 33 (7.0) 8 (5.2)
Other 37 (4.4) 12 (4.2) 25 (4.5) 2 (6.9) 4 (2.1) 18 (3.8) 13 (8.4)
3-drug combinations 104 (100) 58 (100) 46 (100) 3 (100) 31 (100) 58 (100) 12 (10)
Diuretic plus ACE inhibitor plus CCB
- Monopreparation
2 (1.9) 2 (3.4) - - - 1 (1.7) 1 (8.3)
Diuretic plus beta-blocker plus 2
- Monopreparation 57 (54.8) 27 (46.6) 30 (65.2) 1 (33.3) 20 (64.5) 30 (51.7) 6 (50.0)
Diuretic plus antiadrenergic agents plus 2
- Monopreparation
6 (5.8) 5 (8.6) 1 (2.2) - 4 (12.9) 2 (3.4) -
Other 39 (37.5) 24 (41.4) 15 (32.6) 2 (66.7) 7 (22.6) 25 (43.1) 5 (41.7)
1 Calcium channel blocker, 2 CCB, ACE inhibitor, angiotensin II antagonist, alpha-blocker, or dihydrazineB
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Table 4: Prescription of monotherapies for comorbidities
Antihypertensives Total Without 
comorbidities
Comorbidities3
Diabetes
mellitus
Renal
insufficiency
Hypercholes
terolaemia
CHD Post
myocardial
infarction
Heart
failure
Stroke Obesity Asthma/
COPD
[N (%)] [n (%)] [n (%)] [n (%)] [n (%)] [n (%)] [n (%)] [n (%)] [n (%)] [n (%)] [n (%)]
CCB1 527 (17.1) 88 (18.6) 55 (15.9) 26 (20.5) 97 (15.4) 58 (14.5) 12 (20.0) 12 (18.8) 56 (20.4) 47 (13.6) 76 (20.8)
- with CAM2 14 52-1 1 - - 2 - 3
Diuretic 514 (16.7) 77 (16.2) 46 (13.3) 27 (21.3) 58 (9.2) 73 (18.3) 14 (23.3) 15 (23.4) 54 (19.6) 63 (18.2) 87 (23.8)
- with CAM 41 19 2 1 4 3 - - 2 5 5
Beta-blocker 882 (28.7) 151 (31.9) 113 (32.8) 20 (15.7) 225 (35.7) 114 (28.5) 11 (18.3) 8 (12.5) 61 (22.2) 96 (27.7) 83 (22.7)
- with CAM 36 13 3 - 8 3 - - 4 2 3
ACE inhibitor 729 (23.6) 94 (19.8) 75 (21.7) 37 (29.1) 147 (23.3) 113 (28.3) 17 (28.3) 21 (32.8) 79 (28.7) 85 (24.6) 61 (16.7)
- with CAM 33 64 36 9 - - 2 2 1
Angiotensin II 
antagonist
363 (11.8) 64 (13.5) 50 (14.5) 11 (8.7) 86 (13.6) 38 (9.5) 5 (8.3) 7 (10.9) 18 (6.5) 48 (13.9) 36 (9.8)
- with CAM 23 81 14 1 - - 1 4 3
Alpha-1 blocker 20 (0.7) - 1 (0.3) 1 (0.8) 4 (0.6) 1 (0.3) 1 (1.7) - 3 (1.1) 3 (0.9) 6 (1.6)
- with CAM - -- -- - - - - - -
Antiadrenergic agent 44 (1.4) - 5 (1.4) 5 (3.9) 14 (2.2) 3 (0.8) - 1 (1.6) 4 (1.5) 4 (1.2) 8 (2.2)
- with CAM 1 -- -- - - - - - 1
Total 3088 (100) 474 (100) 345 (100) 127 (100) 631 (100) 400 (100) 60 (100) 64 (100) 275 (100) 346 (100) 366 (100)
1 Calcium channel blocker, 2 complementary remedy, 3 double entries possibleB
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Table 5: Prescription of combination therapy for comorbidities
Antihypertensives Total Without
comorbidities
Comorbidities3
Diabetes
mellitus
Renal
insufficiency
Hypercholes
terolaemia
CHD Post
myocardial
infarction
Heart
failure
Stroke Obesity Asthma/
COPD
[N (%)] [n (%)] [n (%)] [n (%)] [n (%)] [n (%)] [n (%)] [n (%)] [n (%)] [n (%)] [n (%)]
2-drug 
combinations
1613 (100) 186 (100) 215 (100) 86 (100) 358 (100) 247 (100) 36 (100) 30 (100) 139 (100) 218 (100) 98 (100)
Diuretic plus
Beta-blocker
Fixed-dose 
coformulation
103 (6.4) 17 (9.2) 11 (5.1) 2 (2.3) 33 (9.2) 14 (5.7) - 1 (3.3) 4 (2.9) 20 (9.2) 1 (1.0)
Monopreparation 106 (6.6) 14 (7.5) 12 (5.6) 5 (5.8) 20 (5.6) 15 (6.1) 2 (5.6) - 9 (6.5) 16 (7.3) 13 (13.3)
CCB1
Fixed-dose 
coformulation
2 (0.1) - - - - 1 (0.4) - - 1 (0.6) - -
Monopreparation 58 (3.6) 7 (3.8) 2 (0.9) 6 (7.0) 8 (2.2) 9 (3.6) 2 (5.6) 3 (10.0) 5 (3.2) 6 (2.8) 10 (10.2)
ACE inhibitor
Fixed-dose 
coformulation
372 (23.1) 43 (23.1) 54 (25.1) 28 (32.6) 75 (20.9) 52 (21.1) 5 (13.9) 16 (53.3) 36 (26.1) 50 (22.9) 13 (13.3)
Monopreparation 132 (8.2) 4 (2.2) 15 (7.0) 7 (8.1) 24 (6.7) 26 (10.5) 5 (13.9) 2 (6.7) 11 (8.0) 21 (9.6) 17 (17.3)
Angiotensin II 
antagonist
Fixed-dose 
coformulation
396 (24.6) 52 (28.0) 61 (28.4) 15 (17.4) 91 (25.4) 49 (19.8) 4 (11.1) 5 (16.7) 31 (22.5) 59 (27.1) 29 (29.6)
Monopreparation 23 (1.4) 2 (1.1) 2 (0.9) 2 (2.3) 7 (2.0) 4 (1.6) - 1 (3.3) 3 (2.2) 1 (0.5) 1 (1.0)
CCB plus
Beta-blocker
Fixed-dose 
coformulation
- -- - - - - - - - -
Monopreparation 77 (4.8) 15 (8.1) 12 (5.6) 5 (5.8) 11 (3.1) 11 (4.5) 4 (11.1) - 8 (5.8) 7 (3.2) 4 (4.1)
ACE inhibitorB
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Fixed-dose 
coformulation
1 (0.1) 1 (0.5) - - - - - - - - -
Monopreparation 65 (4.0) 7 (3.8) 8 (3.7) 6 (7.0) 13 (3.6) 13 (5.3) 3 (8.3) - 4 (2.9) 4 (1.8) 7 (7.1)
Angiotensin II 
antagonist
Fixed-dose 
coformulation
- -- - - - - - - - -
Monopreparation 35 (2.2) 7 (3.8) 2 (0.9) - 8 (2.2) 6 (2.4) 1 (2.8) - 5 (3.6) 5 (2.3) 1 (1.0)
Beta-blocker plus
other 
antihypertensive
Fixed-dose 
coformulation
9 (0.6) 1 (0.5) - - 4 (1.1) 1 (0.4) - 1 (3.3) 2 (1.3) - -
Monopreparation 172 (10.7) 13 (7.0) 26 (12.1) 4 (4.7) 47 (13.1) 37 (14.9) 10 (27.8) 1 (3.3) 13 (9.4) 19 (8.7) 2 (2.0)
Other 62 (3.8) 3 (1.6) 10 (4.7) 6 (7.0) 17 (4.7) 9 (3.6) - - 7 (5.1) 10 (4.6) -
3-drug 
combinations
222 (100) 15 (100) 42 (100) 17 (100) 52 (100) 32 (100) 2 (100) 1 (100) 15 (100) 25 (100) 21 (100)
Diuretic plus ACE 
inhibitor plus CCB
Monopreparation
8 (3.6) - 1 (2.4) 1 (5.9) 2 (3.8) 2 (6.3) - - - - 2 (9.5)
Diuretic plus beta-
blocker plus 2
Monopreparation
120 (54.1) 6 (40.0) 26 (61.9) 5 (29.4) 26 (50.0) 19 (59.4) 1 (50.0) - 9 (60.0) 17 (68.0) 11 (52.4)
Diuretic plus 
antiadrenergic agent 
plus2
Monopreparation
10 (4.5) 2 (13.3) - 2 (11.8) 3 (5.8) 1 (3.1) - - - - 2 (9.5)
Other 84 (37.8) 7 (46.7) 15 (35.7) 9 (52.9) 21 (40.4) 10 (31.3) 1 (50.0) 1 (100) 6 (40.0) 8 (32.0) 6 (28.6)
1 Calcium channel blocker, 2 CCB, ACE inhibitor, angiotensin II antagonist, alpha-blocker, or dihydrazine, 3 double entries possible
Table 5: Prescription of combination therapy for comorbidities (Continued)BMC Family Practice 2009, 10:78 http://www.biomedcentral.com/1471-2296/10/78
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(OR = 0.50; 95% CI 0.41-0.60). With regard to specific
comorbidities, patients with diabetes, for example, were
more likely to be prescribed a beta-blocker (OR = 1.63;
95% CI 1.33-2.00) or an angiotensin II receptor antago-
nist (OR = 1.92; 95% CI 1.42-2.60). Concomitant dis-
eases, such as diabetes mellitus (OR = 0.55; 95% CI 0.42-
0.73), hypercholesterolaemia (OR = 0.59; 95% CI 0.47-
0.75), obesity (OR = 0.74; 95% CI 0.57-0.97), stroke (OR
= 0.54; 95% CI 0.40-0.74), and post myocardial infarction
(OR = 0.37; 95% CI 0.17-0.81), reduced the odds of being
prescribed a CAM remedy.
Power calculation was performed for the odds ratios from
the logistic regression models in table 6 based on the algo-
rithm provided in [35]. At a significance level of 0.05, the
present study had 90% to 100% power to detect a change
of 0.1 in the ORs (exceptions: post myocardial infarction:
0.42-0.68; heart failure 0.40-0.71).
Discussion
A number of studies have investigated physician adher-
ence to hypertension guidelines by analysing patient med-
ical records or physician survey data. Although surveys are
a useful tool, most have methodological limitations that
could cause physician adherence to be underestimated.
The present study relies, instead, on electronic prescrip-
tion records and thus is not subject to the reporting or
retrieval biases inherent to paper-based surveys.
The majority of patients in the present study were treated
with classic antihypertensive monotherapies. Of these
agents, beta-blockers were prescribed most frequently, fol-
Table 6: Multiple logistic regression: Factors associated with special hypertensive medication
CCBs Diuretics Beta-blockers ACE inhibitors Angiotensin II antagonists CAM remedy
Factor Adjusted OR (95% CI)
Gender (male) 1.21
(0.99-1.48)
1.02
(0.83-1.25)
1.15
(0.96-1.36)
1.44
(1.20-1.74)*
1.62
(1.26-2.09)*
0.66
(0.54-0.80)*
Age
(60 years or older)
1.70
(1.34-2.14)*
1.10
(0.88-1.38)
0.50
(0.41-0.60)*
0.87
(0.70-1.06)
0.75
(0.57-0.98)*
1.16
(0.95-1.42)
Comorbidies1 0.87
(0.64-1.18)
1.09
(0.79-1.49)
0.99
(0.76-1.30)
1.57
(1.16-2.11)*
0.46
(0.30-0.69)*
0.91
(0.69-1.21)
Diabetes 1.01
(0.79-1.29)
0.98
(0.76-1.25)
1.63
(1.33-2.00)*
0.85
(0.67-1.07)
1.92
(1.42-2.60)*
0.55
(0.42-0.73)*
Renal insufficiency 1.49
(1.09-2.05)*
1.33
(0.96-1.83)
0.58
(0.41-0.81)*
1.05
(0.76-1.44)
0.66
(0.40-1.10)
0.89
(0.62-1.28)
Hypercholesterolaemia 1.09
(0.87-1.37)
0.70
(0.56-0.88)*
1.29
(1.06-1.56)*
0.93
(0.76-1.15)
1.74
(1.28-2.36)*
0.59
(0.47-0.75)*
CHD 1.00
(0.79-1.26)
1.32
(1.05-1.66)*
1.68
(1.04-1.57)*
1.31
(1.05-1.62)*
1.12
(0.82-1.53)
0.82
(0.64-1.05)
Post myocardial infarction 1.27
(0.78-2.07)
1.43
(0.89-2.32)
1.30
(0.83-2.04)
1.69
(1.09-2.62)*
0.94
(0.47-1.89)
0.37
(0.17-0.81)*
Heart failure 0.72
(0.42-1.23)
0.98
(0.59-1.60)
0.30
(0.16-0.59)*
1.03
(0.64-1.64)
0.93
(0.44-1.97)
0.84
(0.51-1.38)
Stroke 1.22
(0.93-1.50)
1.18
(0.90-1.56)
1.02
(0.79-1.31)
1.22
(0.94-1.58)
1.29
(0.87-1.89)
0.54
(0.40-0.74)*
Obesity 0.98
(0.76-1.28)
1.49
(1.16-1.01)*
0.79
(0.64-0.99)*
1.11
(0.88-1.40)
1.07
(0.77-1.48)
0.74
(0.57-0.97)*
Asthma/COPD 1.41
(1.06-1.88)*
1.69
(1.23-2.23)*
0.94
(0.71-1.23)
0.73
(0.54-0.98)*
1.44
(0.97-2.13)
0.91
(0.67-1.24)
1 at least one of the following indications in table 6
* OR significantly different from 1BMC Family Practice 2009, 10:78 http://www.biomedcentral.com/1471-2296/10/78
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lowed by ACE inhibitors, CCBs, and diuretics. Patient
gender, age, and the presence of comorbidities had a sig-
nificant influence on which treatment was prescribed.
Limitations
The present study has several important limitations. First,
additional data on the hypertension diagnoses are lack-
ing, such as blood pressure, smoking status, and lifestyle
factors. Second, data on subsequent medication use in
patients who switched physicians were unavailable, as
were data on whether a patient was being treated for the
first time with an antihypertensive agent. Third, from a
statistical point of view, the subgroup analyses may be
underpowered in cases where differences were small.
Fourth, although our study population can be regarded as
fairly representative of the overall population of German
physicians specialized in anthroposophic treatment, it is
not representative of all CAM physicians in Germany,
who offer a range of further treatments, including those
from the field of traditional Chinese medicine or integra-
tive treatment programmes including Tai Chi [36,37].
Such treatments are not prescribed frequently, however.
Finally, the present study lacks a direct comparison group.
Further research on this subject would benefit from
including a comparison group of CAM physicians, such as
homoeopaths, or of conventional primary care physi-
cians.
Study population
Of the 3672 eligible patients who received a prescription
during the study, 35.9% (n = 1320) were prescribed con-
ventional and/or CAM treatment for hypertension at least
once. This is comparable to other studies [3,4,38], in
which a large proportion of patients have also been older
(i.e. 65% aged 60 years or more) [39] and a higher CAM
treatment rate was observed in women [40-43]. Although
the types and rates of comorbidities in the present sample
were generally similar to those observed in other surveys,
the rates of diabetes and coronary heart disease experi-
enced by our patients were slightly lower [44], which may
be attributable to higher educational attainment or greater
health awareness among users of complementary medi-
cine [45].
Prescription of antihypertensive treatments and 
adherence to guidelines
Each hypertensive patient received an average of 2.5 pre-
scriptions per year, which at first glance might seem indic-
ative of undertreatment. Indeed, this interpretation would
be in accordance with the results of the HYDRA trial, in
which patients were not provided with adequate hyper-
tensive treatment by their GPs [38]. Nevertheless, the low
average number of prescriptions per year in the present
study may be attributable, at least in part, to two of the
study's above mentioned limitations: (1) the inclusion in
the cohort of patients being treated for the first time with
antihypertensive therapy, and (2) the lack of data on sub-
sequent medication use in patients who switched physi-
cians.
In addition to lifestyle changes, current guidelines recom-
mend initiating antihypertensive treatment using one or
more agents from the following five drug classes: (thi-
azide) diuretics, beta-blockers, CCBs, ACE inhibitors, and
angiotensin receptor blockers. Other substances are rec-
ommended only as adjunctive treatment. In the present
study, only 2% of patients had conventional prescriptions
that did not include any agents from these five classes.
Monotherapies accounted for 64% of all prescribed treat-
ments, and the proportion of patients receiving mono-
therapy was high compared to the German MONICA
Study (50%) and similar to that observed in Israel (64%)
and Finland (59%) [46]. In accordance with other studies,
beta-blockers were prescribed most often, followed by
ACE inhibitors and the combination of a diuretic plus an
ACE inhibitor [39,46]. When available, fixed-dose cofor-
mulations were used frequently, accounting for 55.4% of
all two-drug combinations; this is likely attributable to the
desire to increase patient compliance.
The finding that there are significant differences in the
prescription rates for various antihypertensive agents
according to age, gender, and comorbidities is in accord-
ance with the results reported by Pears et al. [47].
After being adjusted for comorbidity and age, the results
of the present study show that women were less likely to
receive ACE inhibitors or angiotensin II receptor antago-
nists [48,49]. Beta-blockers were prescribed primarily for
patients under the age of 60. These findings concur with
those in comparable national and international surveys of
antihypertensive drug use in primary care [38].
In 2003 Pittrow et al. showed that in German primary
care, hypertensive patients with comorbidities do not
receive the individualized treatment recommended in the
current Germany Hypertension Society guidelines. For
example, although CCBs and beta-blockers are the pre-
ferred option in CHD patients with hypertension, ACE
inhibitors and diuretics were prescribed most frequently
[39]. In the present study, there was also a significantly
higher prescription rate for diuretics (OR = 1.32; 95% CI
1.05-1.66) or ACE inhibitors (OR = 1.31; 95% CI 1.05-
1.62) in CHD patients; however, the OR for the use of
beta-blockers, which are recommended in the German
Hypertension Society guidelines, was even higher (1.68;
95% CI 1.04-1.57). For patients with diabetes, the OR for
receiving beta-blockers, which would also address the
high cardiac risk associated with diabetes, was signifi-
cantly greater than 1 (OR = 1.63; 95% CI 1.33-2.00) [39].BMC Family Practice 2009, 10:78 http://www.biomedcentral.com/1471-2296/10/78
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The OR for patients with prior myocardial infarction was
significantly greater than 1 for ACE inhibitors (OR = 1.69;
95% CI 1.09-2.62), which are also recommended in the
guidelines, but there was not a significantly lower pre-
scription rate for CCBs (OR = 1.27; 95% CI 0.78-2.07),
which are not recommended.
The prescription rates for CCBs in patients with heart fail-
ure (12 out of 527 patient, or 2.3%), beta-blockers in
asthma/COPD patients (83 out of 882 patients, or 9.4%),
and alpha-1-blockers in patients with renal insufficiency
(1 out of 20 patients, or 5.0%) - all of which are contrain-
dicated in the respective patient group - were below 10%.
After adjustment for other factors, multiple logistic regres-
sion did not result in significantly lower prescription rates
for CCBs in patients with heart failure (OR = 0.72; 95% CI
0.42-1.23) or for beta-blockers in patients with asthma/
COPD (OR = 0.94; 95% CI 0.71-1.23).
CAM remedies
Although CAM remedies are not recommended in any of
the currently available guidelines, they were included in
19.1% of the prescriptions in the present study. This is not
surprising considering that most patients who visit CAM
physicians likely do so because they are seeking alterna-
tive treatments. It may be that this group of patients had
only mild hypertension and received CAM remedies in
addition to any conventional treatment and recommen-
dations for lifestyle changes. The results of the present
study strongly suggest that CAM remedies were prescribed
mainly as adjuncts to antihypertensive monotherapy,
most likely as a way to stimulate and harmonize the
rhythmic system, assisting the body in regulating blood
pressure with its own resources [50]. As expected, CAM
medication was prescribed primarily to women and
patients without comorbidities [40-43]. Altogether, the
prescription rate for CAM remedies among patients with
hypertension was very low compared to that among
patients with other diseases, such as acute upper respira-
tory tract infections (79.8%), otitis media, or dorsopa-
thies, in the same network of physicians [51].
Elderly patients with hypertension
Due to methodological limitations, most earlier studies
on hypertension have excluded patients older than 65,
thus failing to evaluate a subgroup of patients whose
importance will only increase in the coming decades. The
Hyvet study published in 2008 [52] was therefore an
important addition to the literature, demonstrating the
benefits of treating hypertension in patients aged 80 years
or older. In accordance with current German Hyperten-
sion Society guidelines, the results of the present study
show higher prescription rates for CCBs and diuretics in
elderly patients, as well as an almost equal distribution of
classic antihypertensive monotherapies among patients
aged 80 years and older.
Conclusions
This paper is the first to provide insight into the hyperten-
sion treatment strategies of physicians specialized in CAM
treatment using routine data from practice information
systems. Despite the limitations of the available data, it
can be concluded that the large majority of antihyperten-
sive treatments prescribed by CAM physicians in the
present study were compliant with the current guidelines
of the German Hypertension Society. Deviations from
these guidelines were seen in one of every seven patients
receiving some form of CAM treatment.
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